# Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

> **NCT06863480** · PHASE1 · RECRUITING · sponsor: **University of Florida** · enrollment: 30 (estimated)

## Conditions studied

- Aneurysmal Subarachnoid Hemorrhage
- Delayed Cerebral Ischemia

## Interventions

- **DRUG:** tocilizumab-aazg (TYENNE)

## Key facts

- **NCT ID:** NCT06863480
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2028-07-30
- **Final completion:** 2028-10-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06863480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06863480, "Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06863480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*